Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

Inclusion criteria

• Provision of written informed consent, or assent with parental or guardian written consent.
• Mean ≥ 10 O. volvulus microfilariae/mg skin, determined by four skin snips
• Living in a village selected for the study.
• Age ≥ 12 years.
• All female participants of childbearing potential must commit to the use of a reliable method of birth control for the duration of treatment and until 3 months after completion of dosing with investigational product.

Exclusion criteria

• Pregnant or breast-feeding.
• Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.
• Has received ivermectin, oral diethylcarbamazine (DEC) or doxycycline (for > 2 weeks) within 6 months of Baseline.
• Has received treatment with an investigational agent within the last 30 days (or 5 half-lives, whichever is longer) prior to Baseline.
• Known or suspected allergy to ivermectin or moxidectin or their excipients.
• Self-reported planned or ongoing activities within the study period that would make it unlikely that a participant will be available for all planned treatment rounds and follow-up examinations.
• Weight > 88 kg.
• Infection with Loa loa.